The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InOppenheimer analyst Trevor Allred has issued a highly bullish outlook for Dianthus Therapeutics (DNTH), setting a new price target of $145. This target implies a potential upside of approximately 79.28% from current levels, reflecting strong confidence in the company's clinical pipeline. The stock responded positively to the news, surging 23.74% to reach $80.68 and hitting a new one-year high of $84.86 during intraday trading. Dianthus has demonstrated remarkable momentum, with its share price increasing 13-fold over the past two years due to advancements in autoimmune disease treatments. The upgrade is primarily driven by progress in therapies for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and other inflammatory conditions. Market experts believe this sustained clinical progress will continue to drive value for the NASDAQ-listed biotech firm.